Indivior Pharmaceuticals Inc

INDVNASDAQHealthcare● Active

$37.39

$-0.23(-0.60%)

Market Cap$4.7B

P/E Ratio—

52W High$41

52W Low$13.42

Avg Volume2.6M

Open$37.70

Beta1.17

Overview

Indivior Pharmaceuticals Inc (INDV) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

INDV · free cash flow · updated Jun 8, 2026

Core FCF metrics

INDV · FCF · TTM · margin & CAGR

Free cash flow was −$93.0M for FY2025 (fiscal year ending 2025-12-31), down 1428.6% year-over-year The FCF margin was -7.5%.

FY2025 Free Cash Flow−$93.0M▼ -1428.6% YoY

Trailing 12M (TTM)−$184.6Mtrailing 4 quarters sum

FCF Margin-7.5%−$93.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

INDV · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$27.0M(66M)−$93.0M▼ 1428.6%-7.5%

FY2024$36.0M(29M)$7.0M▲ +102.0%0.6%

FY2023−$300.0M(53M)−$353.0M▼ 3822.2%-32.3%

FY2022−$4.0M(5M)−$9.0M▼ 102.8%-1.0%

FY2021$353.0M(34M)$319.0M▲ +261.9%40.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

INDV · P/FCF · FCF yield · FCF per share

Indivior Pharmaceuticals Inc (INDV) reported negative free cash flow of −$0.09B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

INDV · cash flow statement · operating / investing / financing

For FY2025, Indivior Pharmaceuticals Inc generated −$27.0M in operating cash flow and spent 66M in capital expenditures, yielding −$93.0M in free cash flow.

Operating Activities

−$27.0M

Cash from core business operations

2025-12-31

Investing Activities

−$66.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$30.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$27.0M) − |CapEx| (66M) = FCF (−$93.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

INDV vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Indivior Pharmaceuticals IncYOU

INDV

−$93.0M-1428.6%-7.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Indivior Pharmaceuticals Inc (INDV) reported free cash flow of −$93.0M for FY2025 (fiscal year ending 2025-12-31), down 1428.6% year-over-year. The FCF margin was -7.5%.

Based on available data, Indivior Pharmaceuticals Inc has maintained positive free cash flow for at least 6 fiscal year(s). FCF peaked at $340.7M in FY2016.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

INDV free cash flow · 8 questions

Indivior Pharmaceuticals Inc free cash flow was −$93.0M for FY2025, down 1428.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$184.6M.

INDV free cash flowINDV FCFINDV FCF 2025INDV free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Indivior Pharmaceuticals Inc · Indivior Pharmaceuticals Inc SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026